Haemonetics Corp's stock price has reached a 52-week high of $109.60, trading just 1% below its peak. The company's market capitalization stands at approximately $5 billion, reflecting an 113.45% increase in stock price over the past year. InvestingPro analysis has given Haemonetics a 'GREAT' score of 3.14 out of 5, noting that it trades below its fair value.
The company's fiscal first-quarter results were strong, with adjusted earnings of $1.14 per share, surpassing the Wall Street/analyst consensus of $1.09. Revenue for the quarter was $339 million, topping expectations of $328.92 million. These positive results have contributed to the stock's upward trajectory.
Haemonetics has also announced a non-exclusive supply agreement with CSL Plasma Inc. The agreement allows CSL Plasma to utilize Haemonetics' NexSys PCS devices with Persona PLUS technology in the United States. The agreement contains no minimum purchase commitments, indicating a flexible and potentially beneficial partnership for both companies.
Analysts have also taken notice of Haemonetics' performance. BTIG has raised its price target for the company to $96 from $84 and maintained a Buy rating. This positive outlook from a respected analyst firm further supports the stock's upward momentum.
